Allergan PLC XEN Gel Stent, REF 5513-001(US Model), Sterile, RX Only, (01)10888628032439 ; Other Model Numbers: 5507-001(Global Model) and 5517-001(Australia model) Implant for glaucoma treatment. Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
XEN Gel Stent, REF 5513-001(US Model), Sterile, RX Only, (01)10888628032439 ; Other Model Numbers: 5507-001(Global Model) and 5517-001(Australia model) Implant for glaucoma treatment.
Brand
Allergan PLC
Lot Codes / Batch Numbers
All Lots within Expiry: US Lot codes: 61650, 61657, 61779, 61780, 61825, 61883, 61884, 61906, 61911, 62578, 62608, 62703, 62812, 62874 and 62941 OUS Lot codes: 61566, 61580, 61626, 61642, 61685, 61846, 61847, 61955, 61966, 62008, 62301, 62053, 62066, 62108, 62130, 62263, 62297, 62318, 62380, 62538, 62636, 62678, 62683, 62719, 62745, 62749, 62769 and 62890
Products Sold
All Lots within Expiry: US Lot codes: 61650, 61657, 61779, 61780, 61825, 61883, 61884, 61906, 61911, 62578, 62608, 62703, 62812, 62874 and 62941 OUS Lot codes: 61566, 61580, 61626, 61642, 61685, 61846, 61847, 61955, 61966, 62008, 62301, 62053, 62066, 62108, 62130, 62263, 62297, 62318, 62380, 62538, 62636, 62678, 62683, 62719, 62745, 62749, 62769 and 62890
Allergan PLC is recalling XEN Gel Stent, REF 5513-001(US Model), Sterile, RX Only, (01)10888628032439 ; Other Model Numbers: 5 due to Residual polishing compounds, that are used in the needle sleeve manufacturing process, may be present on the injector needle. The residual polishing . Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Residual polishing compounds, that are used in the needle sleeve manufacturing process, may be present on the injector needle. The residual polishing compounds could transfer to the patient's eye during procedure possibly resulting in irritation, inflammation, local allergic reaction/ hypersensitivity, iritis, uveitis/sterile endophthalmitis or an intraocular foreign body.
Recommended Action
Per FDA guidance
On October 30, 2019, Allergan mailed a "Urgent Device Recall" letter to consignees via FedEx overnight. In addition to informing the customer about the recall, the letter requested consignees take the following actions: 1. If you have inventory of the recalled products, quarantine product to prevent its use. 2. Conduct a physical count of the affected products in your possession and record the count on the enclosed Business Reply Form (BRF). 3. When returning the recalled product, attach the prepaid FedEx Authorized Return shipping label to the outside of the return carton. Return the recalled product and completed BRF to: Inmar Rx Solutions, Inc. 4332 Empire Rd. Fort Worth, TX 76155 4. If you have no recall product to return, please complete the BRF and return to Inmar Rx Solutions, Inc via fax or email within five (5) business days of receipt. To ensure we are able to account for all recalled product, it is imperative that you return the form. Please return the Reply Form even if no recalled product is present. 5. Please Do Not return any products that are not the subject of this recall. 6. Please contact Inmar Rx Solutions, Inc. if you have any questions about these recall actions at 1-877-756-2970, 9:00am - 5:00pm EST. 7. For Adverse Events/Product Complaints Contact Allergan at: 1-800-624-4261, 9am 6pm EST 8. Medical Information: 1-800-678-1605 option #2, 8:30 am 5:00 pm EST or IR-Medcom@allergan.com 9. FDA contact information for reporting adverse events: Online at www.fda.gov/medwatch/report.htm or call FDA at 1-800-FDA-1088
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026